Alkhaibary Ali, Alassiri Ali H, AlSufiani Fahd, Alharbi Mohammed A
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):82-88. doi: 10.1016/j.hemonc.2018.11.001. Epub 2018 Dec 8.
OBJECTIVE/BACKGROUND: Glioblastoma (GB) is the most common primary malignant brain tumor in adults. Ki-67 is a nonhistone nuclear protein that is expressed by cells entering the mitotic cycle and is associated with the transcription of ribosomal RNA (rRNA). In gliomas, the extent of expression of Ki-67 is roughly proportional to the histologic grade. Over the years, association studies were conducted trying to link the poor outcome in different types of malignant tumors to the Ki-67 proliferative index. This study is designed to investigate the relationship between the proliferation marker, Ki-67, and the overall survival amongst glioblastoma patients diagnosed between 2006 and 2012 at a single institution in Riyadh, Saudi Arabia.
This is a retrospective cohort study which investigated the status of Ki-67 labeling index in glioblastoma patients diagnosed at King Abdulaziz Medical City, Riyadh, Saudi Arabia, between 2006 and 2012. The Kaplan-Meier survival analysis was used to assess the overall survival (OS) and the Mantel-Cox log-rank test was used to compare the survival curves. Multivariate analysis using Cox proportional-hazards model was used to investigate other factors that might influence the overall survival.
A total of 44 glioblastoma patients were included in the study. The median age at diagnosis was 56 (1-91) years. The 12-month survival rate for all glioblastoma patients was 48%. The median survival for patients with Ki-67 labeling index of ≤27%, and >27% was 11 months and 14 months, respectively.
The difference between the survival curves of patients with Ki-67 labeling index of ≤27%, and Ki-67 of >27% was statistically insignificant (p = .130). Therefore, Ki-67 labeling index alone cannot predict survival in glioblastoma patients.
目的/背景：胶质母细胞瘤（GB）是成人中最常见的原发性恶性脑肿瘤。Ki-67是一种非组蛋白核蛋白，由进入有丝分裂周期的细胞表达，与核糖体RNA（rRNA）的转录相关。在胶质瘤中，Ki-67的表达程度大致与组织学分级成正比。多年来，人们进行了关联研究，试图将不同类型恶性肿瘤的不良预后与Ki-67增殖指数联系起来。本研究旨在调查增殖标志物Ki-67与2006年至2012年在沙特阿拉伯利雅得一家机构诊断的胶质母细胞瘤患者总生存期之间的关系。
这是一项回顾性队列研究，调查了2006年至2012年在沙特阿拉伯利雅得阿卜杜勒阿齐兹国王医疗城诊断的胶质母细胞瘤患者的Ki-67标记指数状况。采用Kaplan-Meier生存分析评估总生存期（OS），采用Mantel-Cox对数秩检验比较生存曲线。使用Cox比例风险模型进行多变量分析，以研究可能影响总生存期的其他因素。
本研究共纳入44例胶质母细胞瘤患者。诊断时的中位年龄为56（1-91）岁。所有胶质母细胞瘤患者的12个月生存率为48%。Ki-67标记指数≤27%和>27%的患者中位生存期分别为11个月和14个月。
Ki-67标记指数≤27%和>27%患者的生存曲线差异无统计学意义（p = 0.130）。因此，仅Ki-67标记指数不能预测胶质母细胞瘤患者的生存期。
